Prophase Labs Inc
NASDAQ:PRPH

Watchlist Manager
Prophase Labs Inc Logo
Prophase Labs Inc
NASDAQ:PRPH
Watchlist
Price: 0.3626 USD -18.97% Market Closed
Market Cap: 2.1m USD

Prophase Labs Inc
Investor Relations

ProPhase Labs, Inc. is a medical science and technology company. The company is headquartered in New York City, New York and currently employs 129 full-time employees. The firm operates through two segments: diagnostic services and consumer products. The diagnostic services segment provides COVID-19 diagnostic information services to a range of customers in the United States, including health plans, third-party payers and government organizations. The consumer products segment is engaged in the research, development, manufacture, distribution, marketing and sale of over-the-counter (OTC) consumer healthcare products and dietary supplements in the United States and also provide personal genomics products and services. The firm is also engaged in the development and marketing of dietary supplements under the TK Supplements brand. The Company’s TK Supplements product line includes Legendz XL, a male sexual enhancement and Triple Edge XL, an energy and stamina booster.

Show more
Loading
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare
Last Earnings Call
Fiscal Period
Q3 2025
Call Date
Nov 19, 2025
AI Summary
Q3 2025

Cash Collection Catalyst: ProPhase expects to begin collecting significant cash from Crown Medical's efforts to recover up to $150 million in overdue COVID test payments, with management targeting at least $50 million net.

Proxy Vote Urgency: Management repeatedly urged shareholders to vote on the proxy, emphasizing its importance for strategic flexibility, potential deals, and NASDAQ compliance.

Reverse Stock Split: A reverse stock split is likely to maintain NASDAQ listing if needed; management argued it may not negatively impact share value and could help facilitate growth opportunities.

Strategic Initiatives: Multiple M&A and partnership opportunities are being explored, including a potential crypto treasury strategy and deals involving the BE-Smart esophageal cancer test.

Business Restructuring: The company has sold manufacturing assets, shut down the Nebula Genomics lab, and significantly reduced overhead to improve financial flexibility.

BE-Smart Cancer Test: The esophageal cancer diagnostic test, backed by Mayo Clinic and recently published in a major journal, is seen as a potential major value driver, with management suggesting it could be worth multiples of the current market cap.

Funding Options: The company is using debt and has not yet drawn on its ATM facility, with several parties willing to provide funding ahead of Crown Medical collections.

Undervalued Assets: Management sees a major disconnect between current market cap (around $12 million) and the underlying value of assets, expressing confidence in future upside.

Key Financials
Market Capitalization
$12 million
Shares Outstanding
46.1 million
Crown Medical Uncollected Claims
$150 million
Earnings Call Recording
Other Earnings Calls

Management

Mr. Ted William Karkus
Chairman & CEO
No Bio Available
Mr. Jed A. Latkin
Chief Operating Officer & Head of Finance Department
No Bio Available
Mr. Sergio Miralles
Executive VP & Chief Information Officer
No Bio Available
Mr. Kamal Obbad
Senior VP and Director of Sales & Marketing - Nebula Genomics
No Bio Available
Mr. Jason Karkus
President of Nebula Genomics
No Bio Available
Mr. Lance Bisesar
Corporate Controller
No Bio Available

Contacts

Address
NEW YORK
New York City
711 Stewart Ave, Suite 200, Garden City
Contacts
+12153450919.0
www.prophaselabs.com